Lyell Immunopharma LYEL 深 沪
已收盘 10-23 16:00:00 美东时间
9.39
+0.010
+0.11%
华盛通- 最 高9.445
- 今 开9.33
- 成交量 10.16万股
- 最 低 9.05
- 昨 收 9.38
- 总市值 2.30亿
- 52周最高 45.00
- 市盈率 静 --
- 换手率 0.41%
- 52周最低 7.195
- 委 比 -29.73%
- 总股本 2450.51万
- 历史最高 396.80
- 量 比 0.65
- 振 幅 4.21%
- 历史最低 7.195
- 每 手 1
- 风险率 6.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lyell Immunopharma收跌0.85%，成交额159.65万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:44
美股大行评级 | Adobe绩后获多家大行齐升目标价！最高看多至270美元；甲骨文绩后现多空分歧
今日重点评级关注：Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从10美元升至10.5美元；摩根士丹利：维持Aurora Innovation"超配"评级，目标价从14美元升至18美元
09-14 16:05
Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target
Needham analyst Gil Blum reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Buy and maintains $44 price target.
09-11 19:17
Lyell Immunopharma advances LYL273 CAR T program
Lyell Immunopharma ( ($LYEL) ) has issued an update. On September 10, 2026, Lye...
09-11 04:29
Lyell Immunopharma Completes Transfer For LYL273 Candidate To LyFE Manufacture Center In Washington
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced successful completion of the planned technology transfer for LYL273, a guanylyl cyclase C (GCC)-ta...
09-11 04:07
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
Lyell Immunopharma announced the successful completion of technology transfer for LYL273 to its LyFE Manufacturing Center following FDA review. The Phase 1/2 trial continues with additional patients dosed using the improved manufacturing process to determine the recommended Phase 2 dose and optimize safety management. Additional clinical data and an End-of-Phase 1 FDA meeting are expected in 2027. LYL273 is a CAR T-cell therapy targeting metastat...
09-10 20:05
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
Stifel Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $36
Stifel analyst Stephen Willey initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with a Buy rating and announces Price Target of $36.
08-06 18:08
美股大行评级 | 富国银行上调闪迪目标价从1250美元升至1620美元；最高132美元！高盛、大小摩等多家机构上调通用汽车目标价
今日重点评级关注：HC Wainwright & Co.：维持IREN"买入"评级，目标价从85美元升至90美元；BTIG：维持FTAI Aviation"买入"评级，目标价从340美元升至400美元
07-23 13:42
